IRIS
MUSUMECI, FRANCESCA MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.287
AS - Asia 1.592
NA - Nord America 1.347
Continente sconosciuto - Info sul continente non disponibili 282
SA - Sud America 107
AF - Africa 23
OC - Oceania 1
Totale 12.639
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.043
US - Stati Uniti d'America 1.284
SG - Singapore 609
CN - Cina 415
VN - Vietnam 269
FR - Francia 85
HK - Hong Kong 85
BD - Bangladesh 71
BR - Brasile 57
JP - Giappone 54
DE - Germania 34
FI - Finlandia 26
CA - Canada 23
AR - Argentina 21
GB - Regno Unito 21
ES - Italia 18
TW - Taiwan 18
MX - Messico 17
IN - India 14
NL - Olanda 14
KR - Corea 11
JM - Giamaica 9
CH - Svizzera 7
CL - Cile 7
CO - Colombia 7
GR - Grecia 7
RU - Federazione Russa 7
IQ - Iraq 6
ID - Indonesia 5
PH - Filippine 5
SA - Arabia Saudita 5
CR - Costa Rica 4
EC - Ecuador 4
NP - Nepal 4
PT - Portogallo 4
PY - Paraguay 4
TR - Turchia 4
ZA - Sudafrica 4
DZ - Algeria 3
ET - Etiopia 3
IE - Irlanda 3
PA - Panama 3
PK - Pakistan 3
PL - Polonia 3
SN - Senegal 3
TH - Thailandia 3
VE - Venezuela 3
AZ - Azerbaigian 2
BY - Bielorussia 2
EG - Egitto 2
HU - Ungheria 2
KE - Kenya 2
MA - Marocco 2
NI - Nicaragua 2
PE - Perù 2
SE - Svezia 2
SI - Slovenia 2
SV - El Salvador 2
UA - Ucraina 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AT - Austria 1
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MY - Malesia 1
NE - Niger 1
SC - Seychelles 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 12.357
Salva come PNG Salva come JPEG
Città #
Genova 4.326
Genoa 2.985
Rapallo 812
Vado Ligure 769
San Jose 342
Singapore 303
Ashburn 160
Council Bluffs 113
Ho Chi Minh City 80
Lauterbourg 78
Beijing 73
Hanoi 73
Hong Kong 55
Tokyo 46
New York 45
Los Angeles 32
Frankfurt am Main 30
Santa Clara 26
Helsinki 25
Chicago 18
Rome 15
Bordighera 14
Milan 14
Boardman 13
Da Nang 13
Mexico City 12
Buffalo 11
Haiphong 11
Naples 11
Dallas 10
St Louis 10
Atlanta 8
Phoenix 8
Amsterdam 7
Biên Hòa 7
Orem 7
Seattle 7
São Paulo 7
Tianjin 7
Athens 6
Montreal 6
San Francisco 6
Baltimore 5
Brooklyn 5
City of London 5
Las Vegas 5
Madrid 5
Pisa 5
Quảng Ngãi 5
Santiago 5
Taipei 5
Zurich 5
Baghdad 4
Bogotá 4
Detroit 4
Dhaka 4
Dobong-gu 4
Hải Dương 4
Kingston 4
Miami 4
Paris 4
Phủ Lý 4
Seoul 4
Thái Bình 4
Tukwila 4
Turin 4
Van Nuys 4
Addis Ababa 3
Alessandria 3
Birmingham 3
Buenos Aires 3
Cleveland 3
Columbus 3
Dakar 3
Denver 3
Des Moines 3
Draper 3
Dublin 3
Easton 3
El Paso 3
Fort Myers 3
Ha Kwai Chung 3
Hangzhou 3
Houston 3
Hyderabad 3
Johannesburg 3
Lawrenceville 3
Minneapolis 3
Nashville 3
New Delhi 3
Ottawa 3
Panama City 3
Philadelphia 3
Portland 3
Richardson 3
Salt Lake City 3
San Diego 3
San José 3
Taichung 3
Washington 3
Totale 10.810
Salva come PNG Salva come JPEG
Nome #
Analogs, formulations and derivatives of imatinib: A patent review 207
SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW 4-AMINO-PYRAZOLO[3,4-d]PYRIMIDINES AS POTENTIAL SRC KINASE INHIBITORS 204
A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors. 203
ATP-competitive inhibitors of mTOR: an update. 195
Click Chemistry, A Potent Tool in Medicinal Sciences 192
An update on dual Src/Abl inhibitors 188
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma 186
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant 185
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. 184
Bcr-Abl tyrosine kinase inhibitors: A patent review 180
Fyn kinase in brain diseases and cancer: the search for inhibitors. 179
The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme 165
3-Cyano-4,6-diphenyl-pyridine amino acid derivatives active as influenza A polymerase inhibitors 160
Src kinase inhibitors: an update on patented compounds 156
Matrine in association with FD‑2 stimulates F508del‑cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809 155
A1 receptors ligands: past, present and future trends. 154
Water Solubility Enhancement of Pyrazolo[3,4-d]pyrimidine Derivatives via Miniaturized Polymer–Drug Microarrays 154
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia 154
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors 153
Pyrrolo[2,3-d]pyrimidines as kinase inhibitors 152
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 152
Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies 151
An Update on JAK Inhibitors 148
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment 147
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. 146
Exploring SAR of a new generation of pyrazolo[3,4-d]pyrimidines as Fyn tyrosine kinase inhibitors 146
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. 146
Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells 143
In silico identification and biological evaluation of novel selective serum/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold 141
Synthesis of a small library of potential SGK1 inihibitors 141
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model 137
6-Substituted pyrazolo[3,4-d]pyrimidines: new promising compounds in the fight against Neuroblastoma 137
Combining repositioning and de novo synthesis of pyrazolo[3,4-d]pyrimidines to discover potent SIRT-2 inhibitors 136
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. 136
Pyrazolo[3,4-d]pyrimidine active on neuroblastoma cells 136
CYP-dependent metabolism of antitumor pyrazolo[3,4-d]pyrimidine derivatives is characterized by an oxidative dechlorination reaction. 135
Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors 134
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. 133
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells 133
Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists. 132
SGK1 as a new target for anticancer agents: a hit-to-lead study 129
Pyrazolo[3,4-d]pyrimidines as tyrosine kinase inhibitors: synthesis and biological evaluation 129
Novel dual Src/Abl inhibitors for hematologic and solid malignancies. 128
SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation 126
PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AS SIRTUIN INHIBITORS: DESIGN, SYNTHESIS AND PRELIMINARY in vitro EVALUATION 125
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives active in a preclinical glioblastoma model. 123
The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells 123
Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells 121
A family of nitrogen-containing heterocycles as sirtuin inhibitors: synthesis and invitro biological evaluation 120
Pyrazolo[3,4-d]pyrimidines as Sirtuin Inhibitors: A Preliminary Synthetic and Biological Study 119
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling 118
Hck inhibitors as potential therapeutic agents in cancer and HIV infection 117
Identification of a new family of pyrimidine and pyridine derivatives as disruptors of the viral RNA-dependent RNA polymerase 116
Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors 115
Selective chemical oxidation of risperidone: a straightforward and cost-effective synthesis of paliperidone 114
Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors 114
Synthesis of heterocyclic compounds to be tested as potentiators or correctors of mutant CFTR in cystic fibrosis 112
In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity 112
Starch/Poly(glycerol-adipate) Nanocomposites: A Novel Oral Drug Delivery Device 111
Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor 110
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines 110
Synthesis of a new generation of pyrazolo[3,4-d]pyrimidine as SGK-1 inhibitors. 109
Synthesis of a new generation of pyrazolo[3,4-d]pyrimidines as Fyn inhibitors 108
Formulation Of Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors For The Treatment Of Glioblastoma Multiforme 108
Synthesis of new pyrazolo[3,4-d]pyrimidines 6-alkyl substituted Bcr-Abl tyrosine kinase inhibitors 107
The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the64CuCl2in Human Glioblastoma Multiforme Cells 106
Substituted pyrazolo[3,4-b]pyridines as human A(1) adenosine antagonists: Developments in understanding the receptor stereoselectivity 105
Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment 104
Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors 104
Formulated pyrazolo[3,4-d]pyrimidines active on GBM cell lines 103
New Insights into the LANCL2-ABA Binding Mode towards the Evaluation of New LANCL Agonists 100
One-pot synthesis of indolyl- pyrrolones as Pim1 inhibitors 100
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme 99
The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cells 95
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment 93
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA–PB1 Subunits Interaction 93
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives active against the T315I Abl mutation. 93
Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist’s perspective 92
Inhibition of serum- and glucocorticoid-induced kinase 1 ameliorates hydrocephalus in preclinical models 90
Synthesis of pyrazolo[3,4-d]pyrimidines active on Bcr-Abl T315I mutation. 90
Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme 90
Sweet Cherry Extract as Permeation Enhancer of Tyrosine Kinase Inhibitors: A Promising Prospective for Future Oral Anticancer Therapies 87
Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-d]pyrimidines Kinase Inhibitors 86
Insight into Fyn and SGK1 kinases as new targets in medicinal chemistry: design and synthesis of pyrazolo[3,4-d]pyrimidine libraries 85
Insights into RNA-dependent RNA Polymerase Inhibitors as Anti-influenza Virus Agents 84
Synthesis of a new series of optimized pyrazolo[3,4‑d]pyrimidines as Src Inhibitors 84
In silico exploration of LANCL2-ABA binding mode towards the identification of novel LANCL2 agonists 84
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective 82
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma 79
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment 77
Applying molecular hybridization to design a new class of pyrazolo[3,4-d] pyrimidines as Src inhibitors active in hepatocellular carcinoma 77
Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective 75
Synthesis of hybrid small molecules as potential PA-PB1 heterodimer disruptors of Influenza virus Polymerase 71
Development of a new potential theranostic prodrug for targeting glioblastoma multiforme 68
Design, synthesis, and biological evaluation of a new series of pyrazolo[3,4-d]pyrimidines active as SGK1 inhibitors. A lead optimization study. 67
IN SILICO INVESTIGATION OF LANCL-2 ACTIVATION MECHANISM: THE CASE OF BT-11 (OMILANCOR). 67
Targeting Sirtuins with Pyrazolo[3,4-d]pyrimidines: A Synthetic and Biological Feasibility Study 66
Synthesis of pyrazolo[3,4-d]pyrimidine derivatives endowed with activity against the T315I Abl mutation 65
New potential anti-flu agents acting by disrupting the PA-PB1 interaction of viral polymerase. 64
Structure-Based Virtual Screening (SBVS) for the discovery of Sirtuin-2 inhibitors 62
Totale 12.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.409
article - articoli 28.459
book - libri 0
conference - conferenze 12.950
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.818
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022891 16 38 77 104 18 76 37 214 75 62 40 134
2022/2023997 95 90 7 133 125 164 0 72 173 8 115 15
2023/2024657 19 76 17 94 45 52 34 25 38 43 66 148
2024/20251.957 48 122 89 101 272 214 196 318 64 137 154 242
2025/20264.146 401 94 369 214 598 356 630 299 318 435 214 218
2026/2027370 370 0 0 0 0 0 0 0 0 0 0 0
Totale 12.639